|
|
ARIZONA HOUSE OF REPRESENTATIVES57th Legislature, 2nd Regular Session |
House: HHS DPA 10-2-0-0 |
HB 2617: insurance; prostate cancer; cost sharing
Sponsor: Representative Blackman, LD 7
Caucus & COW
Overview
Prohibits health care insurers that issue, amend or renew a policy or contract, beginning January 1, 2027, from imposing cost sharing requirements for diagnostic prostate cancer screenings for high-risk subscribers.
History
Health care insurers include disability insurers, group disability insurers, blanket disability insurers, health care services organizations, hospital service corporations and medical service corporations (A.R.S. § 20-1379).
Laws 2014, Chapter 255 prohibits an insurance policy, contract or evidence of coverage, that covers cancer medications that are injected or intravenously administered by a health care provider and covers patient-administered cancer medications, from requiring a higher copayment, deductible, or coinsurance amount for the patient-administered medications than is required for the provider-administered medications. It allows for an increase in copayment, deductible or coinsurance amounts for cancer medications if the increase is applied generally to other medical or pharmaceutical benefits under the contract, policy or evidence of coverage and is not done to circumvent the legislation. A health insurer is also prohibited from reclassifying benefits with respect to cancer treatment medications in a manner that is inconsistent with this legislation. Cancer treatment medications are prescriptions drugs and biologics that are used to kill, slow or prevent the growth of cancerous cells (A.R.S. §§ 20-841.10, 20-1057.14, 20-1376.05 and 20-1406.06).
Provisions
1. Prohibits a health care insurer that issues, amends or renews a contract or policy on or after January 1, 2027, from imposing cost sharing requirements for diagnostic prostate cancer screenings for high-risk subscribers. (Sec. 1-4)
2. Defines high-risk as:
a. men who are at least 55 years of age;
b. men who carry the breast cancer gene, including the BRCA1 or BRCA2 gene;
c. men who have a family history of prostate cancer; or
d. men who are military veterans and who have been exposed to agent orange. (Sec. 1-4)
3. Specifies that men who have a family history of prostate cancer, includes a first-degree relative who:
a. was diagnosed with prostate cancer;
b. died of prostate cancer;
c. developed a form of cancer that is known to be associated with an increased risk of prostate cancer; or
d. was diagnosed with a genetic mutation that is known to be associated with an increased risk of prostate cancer. (Sec. 1-4)
Amendments
Committee on Health & Human Services
1. Modifies the terms high risk and men who have a family history of prostate cancer. (Sec. 1-4)
---------- DOCUMENT FOOTER ---------
AG/LK HB 2617
2/9/2026 Page 0 Caucus & COW
---------- DOCUMENT FOOTER ---------